NCT05209776 Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy
| NCT ID | NCT05209776 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Arrhythmogenic Right Ventricular Dysplasia |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2022-02-01 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2022-02-01 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.
Eligibility Criteria
Inclusion Criteria: * For cases: * Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria) * Admitted for right ventricle electrophysiologic mapping * For controls \* Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts. Exclusion Criteria: * Diagnostic of systemic chronic inflammatory disease * Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease. * Taking immunosuppressant or immunomodulating medications
Contact & Investigator
Philippe MAURY, MD
PRINCIPAL INVESTIGATOR
University Hospital, Toulouse
Frequently Asked Questions
Who can join the NCT05209776 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Arrhythmogenic Right Ventricular Dysplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05209776 currently recruiting?
Yes, NCT05209776 is actively recruiting participants. Contact the research team at maury.p@chu-toulouse.fr for enrollment information.
Where is the NCT05209776 trial being conducted?
This trial is being conducted at Toulouse, France.
Who is sponsoring the NCT05209776 clinical trial?
NCT05209776 is sponsored by University Hospital, Toulouse. The principal investigator is Philippe MAURY, MD at University Hospital, Toulouse. The trial plans to enroll 80 participants.